0001193125-21-066707 Sample Contracts

AMENDMENT #2 TO PROJECT RIDER #1 COLLABORATION AGREEMENT

Project Rider Amendment • March 3rd, 2021 • Magenta Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Project Rider Amendment
• Filed
  March 3rd, 2021
• Company
  Magenta Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

This Amendment #2 to Project Rider #1 (“Amendment #2”) is entered into effective as of the date of the final signature executing this Amendment #2 (“Amendment #2 Effective Date”) by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”).

SECOND AMENDMENT TO SUBLEASE AGREEMENT

Sublease Agreement • March 3rd, 2021 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts

• Contract Type
  Sublease Agreement
• Filed
  March 3rd, 2021
• Company
  Magenta Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Massachusetts

This SECOND AMENDMENT TO SUBLEASE AGREEMENT (this “Second Amendment”) is dated as of August 19, 2020 (the “Effective Date”) by and between NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC., a Delaware corporation, having an address at 100 Technology Square, Cambridge Massachusetts 02139 (“Novartis”), and MAGENTA THERAPEUTICS, INC., a Delaware corporation, having an address at 50 Hampshire Street, 8th Floor, Cambridge Massachusetts 02139 (“Subtenant”).

AMENDMENT #3 TO PROJECT RIDER #1 COLLABORATION AGREEMENT

Project Rider • March 3rd, 2021 • Magenta Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Project Rider
• Filed
  March 3rd, 2021
• Company
  Magenta Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

This Amendment #3 to Project Rider #1 (“Amendment #3”) is entered into effective as of the date of the final signature executing this Amendment #3 (“Amendment #3 Effective Date”) by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”) (each a “Party” and collectively the “Parties”).

AMENDMENT #1 COLLABORATION AGREEMENT

Collaboration Agreement • March 3rd, 2021 • Magenta Therapeutics, Inc. • Pharmaceutical preparations

• Contract Type
  Collaboration Agreement
• Filed
  March 3rd, 2021
• Company
  Magenta Therapeutics, Inc.
• Industry
  Pharmaceutical preparations

This Amendment #1 (“Amendment #1”) is issued pursuant to the Collaboration Agreement (“Agreement”), effective November 10, 2017, between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match BioTherapies (“BTMB”) and incorporates all of the terms and conditions therein. The effective date of this Amendment shall be December 31, 2020.